Concomitant 0 11 0 11 O
use 12 15 12 15 O
of 16 18 16 18 O
progestational 19 33 19 33 B-treatment
agents 34 40 34 40 I-treatment

Eastern 0 7 41 48 B-clinical_variable
Cooperative 8 19 49 60 I-clinical_variable
Oncology 20 28 61 69 I-clinical_variable
Group 29 34 70 75 I-clinical_variable
( 35 36 76 77 I-clinical_variable
ECOG 36 40 77 81 I-clinical_variable
) 40 41 81 82 I-clinical_variable
performance 42 53 83 94 I-clinical_variable
status 54 60 95 101 I-clinical_variable
0 61 62 102 103 B-lower_bound
- 63 64 104 105 O
3 65 66 106 107 B-upper_bound

Female 0 6 108 114 B-gender
patient 7 14 115 122 I-gender
of 15 17 123 125 O
childbearing 18 30 126 138 O
potential 31 40 139 148 O
must 41 45 149 153 O
have 46 50 154 158 O
a 51 52 159 160 O
negative 53 61 161 169 B-pregnancy
serum 62 67 170 175 I-pregnancy
pregnancy 68 77 176 185 I-pregnancy
test 78 82 186 190 O

For 0 3 191 194 O
two 4 7 195 198 B-treatment
weeks 8 13 199 204 I-treatment
prior 14 19 205 210 I-treatment
to 20 22 211 213 O
first 23 28 214 219 O
day 29 32 220 223 O
of 33 35 224 226 O
study 36 41 227 232 O
drug 42 46 233 237 O
treatment 47 56 238 247 B-treatment
, 56 57 247 248 O
administration 58 72 249 263 O
of 73 75 264 266 O
any 76 79 267 270 O
of 80 82 271 273 O
the 83 86 274 277 O
following 87 96 278 287 O
cytochrome 97 107 288 298 B-treatment
P450 108 112 299 303 I-treatment
3A 113 115 304 306 I-treatment
( 116 117 307 308 I-treatment
CYP3A 117 122 308 313 I-treatment
) 122 123 313 314 I-treatment
inducers 124 132 315 323 I-treatment
: 132 133 323 324 O
phenytoin 134 143 325 334 B-treatment
, 143 144 334 335 O
phenobarbital 145 158 336 349 B-treatment
, 158 159 349 350 O
carbamazepine 160 173 351 364 B-treatment
, 173 174 364 365 O
rifampin 175 183 366 374 B-treatment
, 183 184 374 375 O
rifabutin 185 194 376 385 B-treatment
, 194 195 385 386 O
St. 196 199 387 390 B-treatment
John 200 204 391 395 I-treatment
's 204 206 395 397 I-treatment
Wort 207 211 398 402 I-treatment
; 211 212 402 403 O
or 213 215 404 406 O
CYP3A 216 221 407 412 B-treatment
inhibitors 222 232 413 423 I-treatment
: 232 233 423 424 O
ketoconazole 234 246 425 437 B-treatment
, 246 247 437 438 O
itraconazole 248 260 439 451 B-treatment
, 260 261 451 452 O
nefazodone 262 272 453 463 B-treatment
, 272 273 463 464 O
ritonavir 274 283 465 474 B-treatment
, 283 284 474 475 O
nelfinavir 285 295 476 486 B-clinical_variable
, 295 296 486 487 O
indinavir 297 306 488 497 B-treatment
, 306 307 497 498 O
atazanavir 308 318 499 509 B-treatment
amprenavir 319 329 510 520 I-treatment
, 329 330 520 521 O
fosamprenavir 331 344 522 535 B-treatment
, 344 345 535 536 O
boceprevir 346 356 537 547 B-treatment
, 356 357 547 548 O
clarithromycin 358 372 549 563 B-treatment
, 372 373 563 564 O
conivaptan 374 384 565 575 B-treatment
, 384 385 575 576 O
lopinavir 386 395 577 586 B-treatment
, 395 396 586 587 O
posaconazole 397 409 588 600 B-clinical_variable
, 409 410 600 601 O
saquinavir 411 421 602 612 B-clinical_variable
, 421 422 612 613 O
telaprevir 423 433 614 624 B-treatment
, 433 434 624 625 O
telithromycin 435 448 626 639 B-treatment
, 448 449 639 640 O
or 450 452 641 643 O
voriconazole 453 465 644 656 B-treatment

Hemoglobin 0 10 657 667 B-clinical_variable
≥ 11 12 668 669 O
9 13 14 670 671 B-lower_bound
g 15 16 672 673 I-lower_bound
/ 16 17 673 674 I-lower_bound
dL 17 19 674 676 I-lower_bound
, 19 20 676 677 O
without 21 28 678 685 O
transfusion 29 40 686 697 O
support 41 48 698 705 O
within 49 55 706 712 O
7 56 57 713 714 B-upper_bound
days 58 62 715 719 I-upper_bound
preceding 63 72 720 729 O
the 73 76 730 733 O
lab 77 80 734 737 O
assessment 81 91 738 748 O

Histological 0 12 749 761 O
or 13 15 762 764 O
cytological 16 27 765 776 O
documented 28 38 777 787 O
diagnosis 39 48 788 797 O
of 49 51 798 800 O
locally 52 59 801 808 O
advanced 60 68 809 817 O
, 68 69 817 818 O
recurrent 70 79 819 828 O
or 80 82 829 831 O
metastatic 83 93 832 842 B-cancer
( 94 95 843 844 O
Stage 95 100 844 849 B-cancer
IIIB 101 105 850 854 I-cancer
or 106 108 855 857 O
Stage 109 114 858 863 B-cancer
IV 115 117 864 866 I-cancer
) 117 118 866 867 O
NSCLC 119 124 868 873 B-cancer

Life 0 4 874 878 B-clinical_variable
expectancy 5 15 879 889 I-clinical_variable
of 16 18 890 892 O
at 19 21 893 895 O
least 22 27 896 901 O
12 28 30 902 904 B-lower_bound
weeks 31 36 905 910 I-lower_bound

Patients 0 8 911 919 O
must 9 13 920 924 O
have 14 18 925 929 O
recovered 19 28 930 939 O
from 29 33 940 944 O
any 34 37 945 948 O
toxic 38 43 949 954 O
effects 44 51 955 962 O
and 52 55 963 966 O
at 56 58 967 969 O
least 59 64 970 975 O
3 65 66 976 977 B-lower_bound
- 66 67 977 978 O
4 67 68 978 979 B-upper_bound
weeks 69 74 980 985 I-upper_bound
must 75 79 986 990 O
have 80 84 991 995 O
elapsed 85 92 996 1003 O
from 93 97 1004 1008 O
the 98 101 1009 1012 O
last 102 106 1013 1017 O
dose 107 111 1018 1022 O
of 112 114 1023 1025 O
previous 115 123 1026 1034 B-treatment
therapy 124 131 1035 1042 I-treatment
, 131 132 1042 1043 O
prior 133 138 1044 1049 O
to 139 141 1050 1052 O
registration 142 154 1053 1065 O

Patients 0 8 1066 1074 O
shall 9 14 1075 1080 O
provide 15 22 1081 1088 O
results 23 30 1089 1096 O
of 31 33 1097 1099 O
tumor 34 39 1100 1105 B-cancer
testing 40 47 1106 1113 O
for 48 51 1114 1117 O
epidermal 52 61 1118 1127 B-clinical_variable
growth 62 68 1128 1134 I-clinical_variable
factor 69 75 1135 1141 I-clinical_variable
receptor 76 84 1142 1150 I-clinical_variable
( 85 86 1151 1152 I-clinical_variable
EGFR 86 90 1152 1156 I-clinical_variable
) 90 91 1156 1157 I-clinical_variable
mutation 92 100 1158 1166 B-clinical_variable
or 101 103 1167 1169 I-clinical_variable
anaplastic 104 114 1170 1180 I-clinical_variable
lymphoma 115 123 1181 1189 I-clinical_variable
kinase 124 130 1190 1196 I-clinical_variable
( 131 132 1197 1198 I-clinical_variable
ALK 132 135 1198 1201 I-clinical_variable
) 135 136 1201 1202 I-clinical_variable
rearrangement 137 150 1203 1216 O

Patients 0 8 1217 1225 O
who 9 12 1226 1229 O
are 13 16 1230 1233 O
taking 17 23 1234 1240 O
simvastatin 24 35 1241 1252 B-treatment
or 36 38 1253 1255 O
lovastatin 39 49 1256 1266 B-treatment

Patients 0 8 1267 1275 O
who 9 12 1276 1279 O
have 13 17 1280 1284 O
been 18 22 1285 1289 O
treated 23 30 1290 1297 O
with 31 35 1298 1302 O
an 36 38 1303 1305 O
investigational 39 54 1306 1321 O
agent 55 60 1322 1327 O
within 61 67 1328 1334 O
21 68 70 1335 1337 B-upper_bound
days 71 75 1338 1342 I-upper_bound
prior 76 81 1343 1348 I-upper_bound
to 82 84 1349 1351 O
day 85 88 1352 1355 O
1 89 90 1356 1357 O
of 91 93 1358 1360 O
cycle 94 99 1361 1366 O
1 100 101 1367 1368 O

Patients 0 8 1369 1377 O
who 9 12 1378 1381 O
have 13 17 1382 1386 O
had 18 21 1387 1390 O
any 22 25 1391 1394 O
major 26 31 1395 1400 B-treatment
surgery 32 39 1401 1408 I-treatment
within 40 46 1409 1415 O
4 47 48 1416 1417 B-upper_bound
weeks 49 54 1418 1423 I-upper_bound
prior 55 60 1424 1429 I-upper_bound
to 61 63 1430 1432 O
day 64 67 1433 1436 O
1 68 69 1437 1438 O
of 70 72 1439 1441 O
cycle 73 78 1442 1447 O
1 79 80 1448 1449 O

Patients 0 8 1450 1458 O
who 9 12 1459 1462 O
require 13 20 1463 1470 O
treatment 21 30 1471 1480 O
with 31 35 1481 1485 O
systemic 36 44 1486 1494 B-treatment
corticosteroids 45 60 1495 1510 I-treatment
for 61 64 1511 1514 O
serious 65 72 1515 1522 B-chronic_disease
medical 73 80 1523 1530 I-chronic_disease
conditions 81 91 1531 1541 I-chronic_disease
or 92 94 1542 1544 I-chronic_disease
illnesses 95 104 1545 1554 I-chronic_disease
( 105 106 1555 1556 O
e.g. 106 110 1556 1560 O
immunosuppression 111 128 1561 1578 B-treatment
after 129 134 1579 1584 O
organ 135 140 1585 1590 B-treatment
transplantation 141 156 1591 1606 I-treatment
) 156 157 1606 1607 O

Potassium 0 9 1608 1617 B-clinical_variable
and 10 13 1618 1621 O
magnesium 14 23 1622 1631 B-clinical_variable
levels 24 30 1632 1638 I-clinical_variable
within 31 37 1639 1645 O
normal 38 44 1646 1652 O
limits 45 51 1653 1659 O

Pregnant 0 8 1660 1668 B-pregnancy
or 9 11 1669 1671 O
breast 12 18 1672 1678 O
- 18 19 1678 1679 O
feeding 19 26 1679 1686 O

Prior 0 5 1687 1692 B-treatment
therapy 6 13 1693 1700 I-treatment
with 14 18 1701 1705 O
mifepristone 19 31 1706 1718 B-treatment

Serum 0 5 1719 1724 B-clinical_variable
creatinine 6 16 1725 1735 I-clinical_variable
≤ 17 18 1736 1737 O
ULN 19 22 1738 1741 B-upper_bound

Sexually 0 8 1742 1750 O
active 9 15 1751 1757 O
female 16 22 1758 1764 B-gender
patient 23 30 1765 1772 I-gender
f 31 32 1773 1774 O
childbearing 33 45 1775 1787 O
potential 46 55 1788 1797 O
must 56 60 1798 1802 O
be 61 63 1803 1805 O
willing 64 71 1806 1813 B-contraception_consent
to 72 74 1814 1816 I-contraception_consent
use 75 78 1817 1820 I-contraception_consent
non 79 82 1821 1824 I-contraception_consent
- 82 83 1824 1825 I-contraception_consent
hormonal 83 91 1825 1833 I-contraception_consent
contraception 92 105 1834 1847 I-contraception_consent
, 105 106 1847 1848 O
including 107 116 1849 1858 O
condom 117 123 1859 1865 B-contraception_consent
use 124 127 1866 1869 O
by 128 130 1870 1872 O
male 131 135 1873 1877 O
partner 136 143 1878 1885 O
, 143 144 1885 1886 O
and 145 148 1887 1890 O
barrier 149 156 1891 1898 B-contraception_consent
method 157 163 1899 1905 I-contraception_consent
by 164 166 1906 1908 O
the 167 170 1909 1912 O
female 171 177 1913 1919 O
partner 178 185 1920 1927 O
( 186 187 1928 1929 O
diaphragm 187 196 1929 1938 B-contraception_consent
or 197 199 1939 1941 O
cervical 200 208 1942 1950 B-contraception_consent
cap 209 212 1951 1954 I-contraception_consent
both 213 217 1955 1959 O
with 218 222 1960 1964 O
spermicide 223 233 1965 1975 O
) 233 234 1975 1976 O
during 235 241 1977 1983 O
the 242 245 1984 1987 O
treatment 246 255 1988 1997 B-treatment
period 256 262 1998 2004 O
and 263 266 2005 2008 O
for 267 270 2009 2012 O
at 271 273 2013 2015 O
least 274 279 2016 2021 O
3 280 281 2022 2023 B-lower_bound
months 282 288 2024 2030 I-lower_bound
after 289 294 2031 2036 O
the 295 298 2037 2040 O
last 299 303 2041 2045 O
dose 304 308 2046 2050 O
of 309 311 2051 2053 O
the 312 315 2054 2057 O
study 316 321 2058 2063 B-treatment
drug 322 326 2064 2068 I-treatment

Significant 0 11 2069 2080 O
cardiac 12 19 2081 2088 B-chronic_disease
diseases 20 28 2089 2097 I-chronic_disease
includes 29 37 2098 2106 O
second 38 44 2107 2113 O
/ 44 45 2113 2114 O
third 45 50 2114 2119 O
degree 51 57 2120 2126 O
heart 58 63 2127 2132 O
block 64 69 2133 2138 O

Total 0 5 2139 2144 O
serum 6 11 2145 2150 B-clinical_variable
bilirubin 12 21 2151 2160 I-clinical_variable
≤ 22 23 2161 2162 O
1.5 24 27 2163 2166 B-upper_bound
times 28 33 2167 2172 I-upper_bound
ULN 34 37 2173 2176 I-upper_bound

Use 0 3 2177 2180 O
of 4 6 2181 2183 O
cytotoxic 7 16 2184 2193 B-treatment
chemotherapeutic 17 33 2194 2210 I-treatment
agents 34 40 2211 2217 I-treatment
, 40 41 2217 2218 O
erythropoiesis 42 56 2219 2233 B-treatment
- 56 57 2233 2234 I-treatment
stimulating 57 68 2234 2245 I-treatment
agents 69 75 2246 2252 I-treatment
( 76 77 2253 2254 I-treatment
ESA 77 80 2254 2257 I-treatment
) 80 81 2257 2258 I-treatment
, 81 82 2258 2259 O
or 83 85 2260 2262 O
experimental 86 98 2263 2275 B-treatment
agents 99 105 2276 2282 I-treatment
( 106 107 2283 2284 O
agents 107 113 2284 2290 O
that 114 118 2291 2295 O
are 119 122 2296 2299 O
not 123 126 2300 2303 O
commercially 127 139 2304 2316 O
available 140 149 2317 2326 O
) 149 150 2326 2327 O
within 151 157 2328 2334 O
30 158 160 2335 2337 B-upper_bound
days 161 165 2338 2342 I-upper_bound
of 166 168 2343 2345 O
the 169 172 2346 2349 O
first 173 178 2350 2355 O
day 179 182 2356 2359 O
of 183 185 2360 2362 O
study 186 191 2363 2368 O
drug 192 196 2369 2373 O
treatment 197 206 2374 2383 O

Women 0 5 2384 2389 B-gender
with 6 10 2390 2394 O
a 11 12 2395 2396 O
history 13 20 2397 2404 O
of 21 23 2405 2407 O
unexplained 24 35 2408 2419 O
vaginal 36 43 2420 2427 O
bleeding 44 52 2428 2436 O

Women 0 5 2437 2442 B-gender
with 6 10 2443 2447 O
uterine 11 18 2448 2455 B-chronic_disease
hyperplasia 19 30 2456 2467 I-chronic_disease
- 31 32 2468 2469 O
in 33 35 2470 2472 O
pre 36 39 2473 2476 O
- 39 40 2476 2477 O
menopausal 40 50 2477 2487 O
women 51 56 2488 2493 B-gender
hyperplasia 57 68 2494 2505 O
> 69 70 2506 2507 O
18 70 72 2507 2509 B-lower_bound
mm 72 74 2509 2511 I-lower_bound
and 75 78 2512 2515 O
in 79 81 2516 2518 O
post 82 86 2519 2523 O
- 86 87 2523 2524 O
menopausal 87 97 2524 2534 O
women 98 103 2535 2540 O
hyperplasia 104 115 2541 2552 O
of 116 118 2553 2555 O
> 119 120 2556 2557 O
10 120 122 2557 2559 B-lower_bound
mm 122 124 2559 2561 I-lower_bound
Prior 125 130 2562 2567 B-treatment
therapy 131 138 2568 2575 I-treatment
with 139 143 2576 2580 I-treatment
mifepristone 144 156 2581 2593 I-treatment

any 0 3 2594 2597 O
serious 4 11 2598 2605 O
medical 12 19 2606 2613 B-chronic_disease
condition 20 29 2614 2623 I-chronic_disease
or 30 32 2624 2626 O
psychiatric 33 44 2627 2638 B-chronic_disease
illness 45 52 2639 2646 I-chronic_disease
that 53 57 2647 2651 O
will 58 62 2652 2656 O
prevent 63 70 2657 2664 O
the 71 74 2665 2668 O
patient 75 82 2669 2676 O
from 83 87 2677 2681 O
signing 88 95 2682 2689 O
the 96 99 2690 2693 O
informed 100 108 2694 2702 O
consent 109 116 2703 2710 O
or 117 119 2711 2713 O
will 120 124 2714 2718 O
place 125 130 2719 2724 O
the 131 134 2725 2728 O
patient 135 142 2729 2736 O
at 143 145 2737 2739 O
unacceptable 146 158 2740 2752 O
risk 159 163 2753 2757 O
if 164 166 2758 2760 O
he 167 169 2761 2763 O
/ 169 170 2763 2764 O
she 170 173 2764 2767 O
participates 174 186 2768 2780 O
in 187 189 2781 2783 O
the 190 193 2784 2787 O
study 194 199 2788 2793 O

minor 0 5 2794 2799 O
surgery 6 13 2800 2807 B-treatment
within 14 20 2808 2814 O
2 21 22 2815 2816 B-upper_bound
weeks 23 28 2817 2822 I-upper_bound
prior 29 34 2823 2828 I-upper_bound
to 35 37 2829 2831 O
day 38 41 2832 2835 O
1 42 43 2836 2837 O
of 44 46 2838 2840 O
cycle 47 52 2841 2846 O
1 53 54 2847 2848 O

poorly 0 6 2849 2855 O
controlled 7 17 2856 2866 O
hypertension 18 30 2867 2879 B-chronic_disease
; 30 31 2879 2880 O
congestive 32 42 2881 2891 B-chronic_disease
heart 43 48 2892 2897 I-chronic_disease
failure 49 56 2898 2905 I-chronic_disease
of 57 59 2906 2908 O
New 60 63 2909 2912 O
York 64 68 2913 2917 O
Heart 69 74 2918 2923 O
Association 75 86 2924 2935 O
( 87 88 2936 2937 O
NYHA 88 92 2937 2941 O
) 92 93 2941 2942 O
Class 94 99 2943 2948 O
II 100 102 2949 2951 O
or 103 105 2952 2954 O
worse 106 111 2955 2960 O
( 112 113 2961 2962 O
slight 113 119 2962 2968 O
limitation 120 130 2969 2979 O
of 131 133 2980 2982 O
physical 134 142 2983 2991 O
activity 143 151 2992 3000 O
; 151 152 3000 3001 O
comfortable 153 164 3002 3013 O
at 165 167 3014 3016 O
rest 168 172 3017 3021 O
, 172 173 3021 3022 O
but 174 177 3023 3026 O
ordinary 178 186 3027 3035 O
physical 187 195 3036 3044 O
activity 196 204 3045 3053 O
results 205 212 3054 3061 O
in 213 215 3062 3064 O
fatigue 216 223 3065 3072 O
, 223 224 3072 3073 O
palpitation 225 236 3074 3085 O
, 236 237 3085 3086 O
or 238 240 3087 3089 O
dyspnea 241 248 3090 3097 B-chronic_disease
) 248 249 3097 3098 O

significant 0 11 3099 3110 O
ischemic 12 20 3111 3119 B-chronic_disease
heart 21 26 3120 3125 I-chronic_disease
disease 27 34 3126 3133 I-chronic_disease
; 34 35 3133 3134 O
mean 36 40 3135 3139 O
QTc 41 44 3140 3143 B-clinical_variable
interval 45 53 3144 3152 I-clinical_variable
> 54 55 3153 3154 O
480 56 59 3155 3158 B-lower_bound
msec 60 64 3159 3163 I-lower_bound
on 65 67 3164 3166 O
at 68 70 3167 3169 O
least 71 76 3170 3175 O
two 77 80 3176 3179 B-lower_bound
separate 81 89 3180 3188 O
electrocardiograms 90 108 3189 3207 O
( 109 110 3208 3209 O
ECGs 110 114 3209 3213 O
) 114 115 3213 3214 O
prior 116 121 3215 3220 O
to 122 124 3221 3223 O
study 125 130 3224 3229 O
start 131 136 3230 3235 O

